PMID- 31197753
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200929
IS  - 1869-6953 (Print)
IS  - 1869-6961 (Electronic)
IS  - 1869-6961 (Linking)
VI  - 10
IP  - 4
DP  - 2019 Aug
TI  - Lower Renal Threshold for Glucose Reabsorption in Type 1 Diabetes Mellitus (T1DM) 
      May Explain the Smaller Contribution of SGLT2 Inhibitors to the Improvement of 
      Plasma Glucose Control Compared with T2DM.
PG  - 1531-1534
LID - 10.1007/s13300-019-0649-8 [doi]
AB  - INTRODUCTION: Previously, we reported that the renal threshold for glucose 
      reabsorption can be measured as the lowest plasma glucose level that correlates 
      with the first detectable appearance of urine glucose. These data revealed 
      significant variations among patients with type 2 diabetes mellitus (T2DM), and 
      there was a significant negative correlation between the renal threshold for 
      glucose reabsorption and HbA1c levels following treatment with the sodium-glucose 
      co-transporter 2 (SGLT2) inhibitor ipragliflozin. Recently approved SGLT 
      inhibitors may not show the same efficacy in patients with T1DM as in those with 
      T2DM unless the renal threshold for glucose reabsorption shows similar levels 
      between the two groups. SGLT2 inhibitors improve plasma glucose control in 
      patients with T2DM by reducing glucose reabsorption via the epithelial cells of 
      the proximal tubule. METHODS: The renal threshold for glucose reabsorption was 
      defined as the minimum blood glucose concentration that results in the presence 
      of measurable glycosuria in at least 12 measurements. RESULTS: The renal 
      threshold for glucose reabsorption in patients with T2DM [n = 64; 201.8 +/- 33.6 
      (range 121-268) mg/dL] was significantly higher than that in patients with T1DM 
      [n = 33; 171.0 +/- 33.0 (range 76-259) mg/dL; p = 0.00022]. CONCLUSION: The renal 
      threshold for glucose reabsorption in patients with T1DM was near the normal 
      range and significantly lower than that in patients with T2DM. The efficacy of 
      the SGLT2 inhibitor was better in patients with a higher renal threshold for 
      glucose reabsorption. Thus, these results indicate that it is advisable to 
      estimate the renal threshold for glucose reabsorption prior to initiating SGLT2 
      inhibitor therapy in patients with T1DM.
FAU - Osaki, Aya
AU  - Osaki A
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, 3-39-15 Showa-Machi, Maebashi, Gunma, Japan.
FAU - Shimoda, Yoko
AU  - Shimoda Y
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, 3-39-15 Showa-Machi, Maebashi, Gunma, Japan.
FAU - Okada, Junichi
AU  - Okada J
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, 3-39-15 Showa-Machi, Maebashi, Gunma, Japan.
AD  - Kan-Etsu Chuo Hospital, 71 Kitahara, Takasaki, Gunma, Japan.
FAU - Yamada, Eijiro
AU  - Yamada E
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, 3-39-15 Showa-Machi, Maebashi, Gunma, Japan.
FAU - Saito, Tsugumichi
AU  - Saito T
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, 3-39-15 Showa-Machi, Maebashi, Gunma, Japan.
FAU - Nakajima, Yasuyo
AU  - Nakajima Y
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, 3-39-15 Showa-Machi, Maebashi, Gunma, Japan.
FAU - Ozawa, Atsushi
AU  - Ozawa A
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, 3-39-15 Showa-Machi, Maebashi, Gunma, Japan.
FAU - Niijima, Yawara
AU  - Niijima Y
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, 3-39-15 Showa-Machi, Maebashi, Gunma, Japan.
AD  - Kan-Etsu Chuo Hospital, 71 Kitahara, Takasaki, Gunma, Japan.
FAU - Okada, Shuichi
AU  - Okada S
AUID- ORCID: 0000-0003-1403-6840
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, 3-39-15 Showa-Machi, Maebashi, Gunma, Japan. okadash@gunma-u.ac.jp.
AD  - Kan-Etsu Chuo Hospital, 71 Kitahara, Takasaki, Gunma, Japan. 
      okadash@gunma-u.ac.jp.
FAU - Yamada, Masanobu
AU  - Yamada M
AD  - Department of Medicine and Molecular Science, Gunma University Graduate School of 
      Medicine, 3-39-15 Showa-Machi, Maebashi, Gunma, Japan.
LA  - eng
PT  - Journal Article
DEP - 20190613
PL  - United States
TA  - Diabetes Ther
JT  - Diabetes therapy : research, treatment and education of diabetes and related 
      disorders
JID - 101539025
PMC - PMC6612335
OTO - NOTNLM
OT  - Renal threshold for glucose reabsorption
OT  - Sodium-glucose co-transporter 2 inhibitor
OT  - Type 1 diabetes mellitus
OT  - Type 2 diabetes mellitus
EDAT- 2019/06/15 06:00
MHDA- 2019/06/15 06:01
PMCR- 2019/06/13
CRDT- 2019/06/15 06:00
PHST- 2019/04/25 00:00 [received]
PHST- 2019/06/15 06:00 [pubmed]
PHST- 2019/06/15 06:01 [medline]
PHST- 2019/06/15 06:00 [entrez]
PHST- 2019/06/13 00:00 [pmc-release]
AID - 10.1007/s13300-019-0649-8 [pii]
AID - 649 [pii]
AID - 10.1007/s13300-019-0649-8 [doi]
PST - ppublish
SO  - Diabetes Ther. 2019 Aug;10(4):1531-1534. doi: 10.1007/s13300-019-0649-8. Epub 
      2019 Jun 13.